Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study

OBJECTIVE: To evaluate the safety and efficacy of hCDR1 (Edratide) in patients with systemic lupus erythematosus (SLE). METHODS: Patients (n=340) with SLE ≥4 ACR criteria (4–11, mean 7) with active disease (SLEDAI-2K of 6–12). Patients were on average 7.1 years post-diagnosis and their organ involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Urowitz, Murray B, Isenberg, David A, Wallace, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538379/
https://www.ncbi.nlm.nih.gov/pubmed/26301100
http://dx.doi.org/10.1136/lupus-2015-000104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538379/
https://www.ncbi.nlm.nih.gov/pubmed/26301100
http://dx.doi.org/10.1136/lupus-2015-000104

Ejemplares similares